4 Analysts Have This to Say About Immuneering
Portfolio Pulse from Benzinga Insights
Analysts have provided various ratings for Immuneering (NASDAQ:IMRX) within the last quarter, with 1 bullish, 2 somewhat bullish, and 1 indifferent. The average 12-month price target for Immuneering is $21.5, which has increased by 53.57% over the past month.
August 08, 2023 | 8:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts' ratings for Immuneering are mostly positive, with an increasing price target, which could potentially boost the stock's performance.
Analysts' ratings are a significant factor that investors consider when making investment decisions. The majority of the ratings for Immuneering are positive, and the increasing price target indicates analysts' growing confidence in the company's performance, which could potentially lead to an increase in the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100